RLFTF News and Press, Mondobiotech Holding AG Basel From 10/06/22

Leading Provider of Food for Special Medical Purposes to Help Maximize Patient Access in Support of PKU GOLIKE ® U.S. Launch GENEVA, SWITZERLAND / ACCESSWIRE / October 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-sta...

NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for U...

Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) said that an investigator initiated trial of Nexodyn for a rare skin disorders called Epidermolysis Bullosa (EB) received IRB approval and will shortly begin enrolling participants. The Swiss company noted that the...

Professor Amy Paller, M.D., will serve as Principal Investigator to evaluate Nexodyn for the management of colonized dystrophic and junctional Epidermolysis Bullosa wounds, an important unmet need in this group of rare inherited skin diseases that affects approximately 250,000 patients...

GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases wit...

GENEVA, SWITZERLAND / ACCESSWIRE / September 12, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases wit...

GENEVA, SWITZERLAND / ACCESSWIRE / September 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with...

GENEVA, SWITZERLAND / ACCESSWIRE / August 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced today that it has filed a Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission (...

Swiss biotech company Relief Therapeutics (RLFT) has filed to uplist its shares to Nasdaq and raise a proposed $20M through a public offering. While the drug developer didn’t specify in its filing the number or pricing of the shares to be offered, it indicated in its fi...

RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION PR Newswire Release of an ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa. , Aug. 22, 2022 /PRNewswire/ -- ...